<DOC>
	<DOCNO>NCT00248131</DOCNO>
	<brief_summary>This multicenter , open-label extension study evaluate long-term tolerability safety patient complete study CSMS995 0802 . During extension study , patient receive open-label treatment octreotide acetate microspheres every 4 week 2 year treatment moderately severe severe NPDR low risk PDR .</brief_summary>
	<brief_title>Extension Study Long-term Safety Tolerability Octreotide Acetate Patients With Moderately Severe Severe Non-proliferative Diabetic Retinopathy Low Risk Proliferative Diabetic Retinopathy</brief_title>
	<detailed_description />
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<criteria>write informed consent provide prior participation extension study successful completion study CSMS995 0802 willingness comply study requirement 8 week interval since completion study CSMS995 0802 premature discontinuation study CSMS995 0802 Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Diabetic retinopathy , octreotide acetate microspheres</keyword>
</DOC>